<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979456</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2018-000721-31</org_study_id>
    <nct_id>NCT03979456</nct_id>
  </id_info>
  <brief_title>RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS</brief_title>
  <acronym>RIDOSE-MS</acronym>
  <official_title>RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized trial of long-term dosage of rituximab in multiple sclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized phase 3 study comparing two dosing regimens of Rituximab in
      long-term treatment of MS. Primary endpoint is no evidence of disease activity (NEDA) in a
      non-inferiority analysis between 12-months dosing interval of 500 mg rituximab with 6-months
      dosing interval. The endpoint is a compound of being free from release, new or enlarging MRI
      lesions and sustained progression of disability measured by EDSS.

      Each patient will have one treating physician responsible for all ongoing medical questions
      and decisions regarding continuation in the study and one examining physician performing the
      blinded Expanded Disability Status Scale examination and assessments of exacerbations. The
      coordinating nurse will administer the study-related tests and administer the rituximab
      infusions. MRI investigations will be performed blinded for the dosing arm allocation.

      Randomization will be performed via a randomization module in the national Swedish MS
      registry. The patients will be randomized in a 1:1 ratio and receive their treatments in
      accordance with clinical practice. Thus, the study will mimic the real-life situation in
      which the treatments will be administered. This will lead to a high degree of validity in
      relation to expected outcome in clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No evidence of disease activity (NEDA)</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of patients maintaining No Evidence of Disease Activity-3 (NEDA-3) during year 2 - 4 of the trial: No relapse, no new T2 lesions (&gt; 3 mm), no EDSS progression in either dose arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No evidence of disease activity (NEDA) in subgroups</measure>
    <time_frame>4 years</time_frame>
    <description>The proportion of patients maintaining NEDA-3 comparing the previous rituximab arm with the previous DMF arm from the RIFUND trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>3 yeas</time_frame>
    <description>Time to first relapse for the two dose arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of new or enlarged lesions on MRI</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patients in each dosing arm without new/enlarging T2 lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of brain atrophy</measure>
    <time_frame>3 years</time_frame>
    <description>Evolution of brain atrophy measured as brain parenchymal fraction (BPF) and corpus callosum area or -volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of confirmed sustained disability</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patient with confirmed progression in EDSS according to pre-specified criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean progression of disability</measure>
    <time_frame>3 years</time_frame>
    <description>The mean change in EDSS over the trial period in the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodegeneration</measure>
    <time_frame>3 years</time_frame>
    <description>The mean change of s-NFL concentration between the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose persistence</measure>
    <time_frame>3 years</time_frame>
    <description>Time to discontinuation of dosing regimen allocation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hypogammaglobulinaemia</measure>
    <time_frame>3 years</time_frame>
    <description>The occurrence of hypogammaglobulinaemia in the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of neutropenia</measure>
    <time_frame>3 years</time_frame>
    <description>The occurrence of neutropenia in the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of infections</measure>
    <time_frame>3 years</time_frame>
    <description>The occurrence of infections in the two dosing arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health economy</measure>
    <time_frame>3 years</time_frame>
    <description>Estimation of societal costs per year to supply the two dosing arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Satisfaction Questionnaire</measure>
    <time_frame>3 years</time_frame>
    <description>Validated scale that evaluate the degree of treatment satisfaction through 10 5- or 7 grade likert-scale questions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>6-month dosing interval</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is receiving standard dose rituximab 500 mg every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month dosing interval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is receiving the comparator dose rituximab 500 mg every 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.</description>
    <arm_group_label>12-month dosing interval</arm_group_label>
    <arm_group_label>6-month dosing interval</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of Relapsing Remitting MS according to the 2017 revised McDonald criteria OR
             one demyelinating episode in conjunction with at least one asymptomatic high intensity
             T2 lesion with size and location compatible with MS

          -  The patient has completed the RIFUND-MS trial and is treated with either of the study
             medications rituximab or DMF at the last visit of the RIFUND trial OR has been treated
             with rituximab with a dose regimen of 500 - 1000 mg followed by 500 mg every 6 months
             for up to two years as part of clinical practice

          -  Age 20 - 52 years (inclusive)

          -  EDSS 0 - 5,5 (inclusive)

          -  The patient is willing and able to give written informed consent, according to the
             judgement of the investigator.

          -  In fertile females, willing to comply with effective contraceptive methods. These
             include birth control pills, surgical sterilization of patient or partner or
             intrauterine device. Non-fertile women is defined as more than 12 months of amenorrhea
             without an alternative medical cause or, in case of ambiguities, an FSH level in the
             postmenopausal range.

        Exclusion criteria:

          -  Diagnosis of Progressive MS

          -  Previous treatment with any &quot;second-line&quot; immunomodulatory drug, eg natalizumab,
             alemtuzumab, fingolimod, or other long-acting immunosuppressive agents.

          -  Pregnant or lactating women s-HCG will be tested on all women at screening, before
             each study-related infu-sion and in any situation where there is a reason to suspect
             pregnancy during the trial, e.g delayed menstrual period more than five days above
             expected time.

          -  Patients having contraindication for or otherwise not compliant with MRI
             investigations

          -  Simultaneous treatment with other immunosuppressive drugs

          -  Active, severe infections Signs of infections are assessed before inclusion and each
             study-related infusion through clinical examination and further evaluated by
             laboratory and other relevant investigations in case of suspected ongoing infection.
             Hepatitis serology (HBsAg and anti-HBc) will be evaluated before treatment onset if
             not tested within the previous three years.

          -  Severe cardiac disorder, e.g signs of congestive heart failure or coronary artery
             disease. This will be evaluated through clinical assessment before inclusion.

          -  Vaccination within 4 weeks of first dose of study medication.

          -  Documented allergy or intolerance to the IP

          -  Severe psychiatric condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Svenningsson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Svenningsson, Professor</last_name>
    <phone>0046812355584</phone>
    <email>anders.svenningsson@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anders Svenningsson</name>
      <address>
        <city>Danderyd</city>
        <state>Stockholm</state>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Svenningsson, Professor</last_name>
      <phone>0046812355584</phone>
      <email>anders.svenningsson@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Älvsborg Hospital</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igal Rosenstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Falun Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joakim Hambraeus, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Sjöblom</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saghlgrenska Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Lycke, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Risedal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karlstad Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rune Johansson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Halland Hospital Kungsbacka</name>
      <address>
        <city>Kungsbacka</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Gilland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Vrethem, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nyköping Hospital</name>
      <address>
        <city>Nyköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Lindeberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capio StGöran Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Ayad, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fredrik Piehl</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Piehl, Professor</last_name>
      <phone>+46 73-671 81 01</phone>
      <email>Fredrik.Piehl@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Fink, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Umeå University</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonatan Saltzer, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala Academiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Burman, Assoc Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gunnarsson, Assoc Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Östersund Hospital</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre de Flon, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anders Svenningsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Relapsing-Remitting</keyword>
  <keyword>Dosing protocols</keyword>
  <keyword>Randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

